Raymond James Maintains Outperform on Abbott Laboratories, Lowers Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Jayson Bedford has maintained an 'Outperform' rating on Abbott Laboratories (NYSE:ABT), but lowered the price target from $123 to $110.
October 19, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Abbott Laboratories' price target has been lowered from $123 to $110 by Raymond James, though the 'Outperform' rating is maintained.
The news is directly about Abbott Laboratories. The lowering of the price target might indicate a potential downside in the short term, but the maintained 'Outperform' rating suggests that the analyst still sees the company as a good investment. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100